Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Hong Kong
/
Pharmaceuticals & Biotech
Create a narrative
WuXi Biologics (Cayman)
SEHK:2269 Community
Create a narrative
WuXi Biologics (Cayman)
Undervalued
Overvalued
WuXi Biologics (Cayman)
WA
Analyst Price Target
Consensus Narrative from 25 Analysts
Follow The Molecule Strategy And Global Expansion Will Secure Future Opportunities
Key Takeaways Robust pipeline growth with new projects and North American focus drive future revenue and stabilize amidst geopolitical tensions. Strong non-COVID revenue growth and strategic partnerships boost earnings and profit margins through high-value deals and technological advantage.
View narrative
HK$21.47
FV
0.3% undervalued
intrinsic discount
12.85%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
2269
WuXi Biologics (Cayman)
Your Fair Value
HK$
Current Price
HK$21.40
24.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
29b
2015
2018
2021
2024
2025
2027
2030
Revenue CN¥29.2b
Earnings CN¥4.5b
Advanced
Set as Fair Value